Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
All Days
Sun, Sep 8
Mon, Sep 9
Poster Schedule
Type here to filter the list
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
A004: Cefepime Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children With Multiple Organ Dysfunction Syndrome
Favorite
5:00 PM – 7:00 PM
ET
A005: Implications of Being Born Small for Gestational Age on the Exposure of Vancomycin & Gentamicin In Neonates
Favorite
5:00 PM – 7:00 PM
ET
A006: Microfluidic Blood-Milk Barrier & Physiologically-based Pharmacokinetic Model to Predict Lofexidine Secretion into Breast Milk
Favorite
5:00 PM – 7:00 PM
ET
A007: Dose Optimization of Cefazolin in Adult Cardiac Surgery With Cardiopulmonary Bypass After Albumin Supplementation
Favorite
5:00 PM – 7:00 PM
ET
A008: Using Clinical Data & Physiologically-based Pharmacokinetic Modelling to Assess the Effect of Hepatic Impairment on Avapritinib Pharmacokinetics to Guide Dose Adjustment
Favorite
5:00 PM – 7:00 PM
ET
A009: A Translational Platform Quantitative Systems Pharmacology Model for Preclinical to Clinical Translation of In Vivo CRISPR-Cas9 Gene Therapy
Favorite
5:00 PM – 7:00 PM
ET
A010: Model-Based Assessment of the Contribution of Fc Proteins & Serum Proteins to the Elevated Clearance of Monoclonal Antibodies
Favorite
5:00 PM – 7:00 PM
ET
011: Evaluation of Prompt Engineering Strategies for Pharmacokinetic Data Analysis With the ChatGPT Large Language Model
Favorite
5:00 PM – 7:00 PM
ET
013: Use of Artificial Intelligence in Drug Development
Favorite
5:00 PM – 7:00 PM
ET
014: Analyzing the Association Between Single Nucleotide Polymorphisms & Combinations of Buprenorphine & Associated Metabolite Concentrations
Favorite
5:00 PM – 7:00 PM
ET
015: Characterizing the Covariates & their Impacts on Statistical Evaluations of Clinical Pharmacology Studies in the 351(k) Biologic License Applications
Favorite
5:00 PM – 7:00 PM
ET
016: Comparative Pharmacokinetics & Bioequivalence Study of Gatifloxacin 200mg Tablets
Favorite
5:00 PM – 7:00 PM
ET
017: Pharmacist Administered Parenteral Medications: A Descriptive Study of a Novel Inpatient Training Program
Favorite
5:00 PM – 7:00 PM
ET
019: Clinical Pharmacology Insights into Dosing Strategies of Approved Antibody-Drug Conjugates
Favorite
5:00 PM – 7:00 PM
ET
020: Integration of the National HIV Curriculum at Accredited Graduate Programs of Pharmacy
Favorite
5:00 PM – 7:00 PM
ET
021: Strategic & Quantitative Recommendations on Bioanalytical Cross-Validation Experiment Design from a Clinical Pharmacology Perspective
Favorite
5:00 PM – 7:00 PM
ET
022: Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants
Favorite
5:00 PM – 7:00 PM
ET
023: FDA & EMA Regulatory Recommendations on Fed Bioequivalence Study in Healthy Subjects vs Patients for Generic Drug Development
Favorite
5:00 PM – 7:00 PM
ET
024: The Drug-Drug Interaction Effect of Steady State Rifampin Exposure on Single Dose Pharmacokinetics of Lazertinib
Favorite
5:00 PM – 7:00 PM
ET
025: No Clinically Meaningful Drug Interaction Between Futibatinib & Digoxin, Rosuvastatin or Quinidine
Favorite
5:00 PM – 7:00 PM
ET
026: Phase I Open Label Study to Evaluate the Effects of Savolitinib on the Pharmacokinetics of P-gp, OATP1B1/3, OCT2, MATE1/2K & OAT1/3 Substrates in Healthy Volunteers
Favorite
5:00 PM – 7:00 PM
ET
027: A Quantitative Evaluation of the Relationship Between Hepatic Extraction Ratio & Change in Plasma Half-Life Following Modulation of CYP3A Activity
Favorite
5:00 PM – 7:00 PM
ET
028: Drug-Drug Interactions of Lirafugratinib
Favorite
5:00 PM – 7:00 PM
ET
029: Physiologically-based Pharmacokinetic Modeling of a Novel HER3-Targeted Antibody-Drug Conjugate, Patritumab Deruxtecan to Assess Pharmacokinetic Drug-Drug Interaction
Favorite
5:00 PM – 7:00 PM
ET
030: Effects of Itraconazole & Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies
Favorite
5:00 PM – 7:00 PM
ET
031: No Increase in the Risk of Liver or Muscle Toxicity in Pegozafermin-treated Patients With Metabolic Dysfunction-Associated Steatohepatitis on Statin Background Therapy
Favorite
5:00 PM – 7:00 PM
ET
032: The Effect of an Acid-reducing Agent, Esomeprazole on Sparsentan Pharmacokinetics in Healthy Volunteers
Favorite
5:00 PM – 7:00 PM
ET
033: Clinical Assessment of Mocravimod as a Victim of Drug-Drug Interactions via CYP3A Metabolism & Transporters
Favorite
5:00 PM – 7:00 PM
ET
034: A Drug-Drug Interaction Study Between ABBV-903 & Midazolam in Healthy Participants
Favorite
5:00 PM – 7:00 PM
ET
035: Potential Epigenetic Opioid-Chemotherapy Drug Interactions
Favorite
5:00 PM – 7:00 PM
ET
036: Endogenous Biomarker Use in Renal Transporter-Mediated Drug Interactions: A Literature Review of Intrinsic, Extrinsic Factors & Disease Impact on Biomarker Levels
Favorite
5:00 PM – 7:00 PM
ET
037: Effect of Omaveloxolone @ Its Metabolites on Corrected QT Interval in Health Subjects
Favorite
5:00 PM – 7:00 PM
ET
038: Lorundrostat Concentration-QTc Results from the First-in-Human Study in Healthy Participants Demonstrate Lack of Relevant Effect & Replaces the Thorough QT Study
Favorite
5:00 PM – 7:00 PM
ET
039: Incidence & Predictors of Stroke Mimic Amongst Patients Treated With Recombinant Tissue Plasminogen Activator: A Retrospective Comparison
Favorite
5:00 PM – 7:00 PM
ET
040: Assessment of Clinical Challenges With Application of Institute for Safe Medication Practices Targeted Medication Safety Best Practice: Injectable Promethazine
Favorite
5:00 PM – 7:00 PM
ET
041: Population Modeling Framework With Adaptive Dosing for Optimizing Clinical Utility of Compounds in Development for Treatment of Solid Tumors
Favorite
5:00 PM – 7:00 PM
ET
042: Pharmacokinetics & Exposure-safety Analyses Across Tumor Types for Ifinatamab Deruxtecan (I-DXd) in the First-in-Human Study IDeate-Pantumor01 (DS7300-A-J101)
Favorite
5:00 PM – 7:00 PM
ET
043: Effects of the Innate Immune System, Body Habitus & Sex on the Pharmacokinetics & Antitumor Response of Anetumab Ravtansine in Patients With Solid Tumors
Favorite
5:00 PM – 7:00 PM
ET
044: Effect of Food on the Pharmacokinetics & Safety Profile of p53 Reactivator Rezatapopt in Healthy Subjects & Patients With Solid Tumors Harboring a
TP53
Y220C Mutation
Favorite
5:00 PM – 7:00 PM
ET
045: Population Pharmacokinetics of GB-5001, a Long-acting Intramuscular Injection of Donepezil, in Healthy Participants
Favorite
5:00 PM – 7:00 PM
ET
046: Exposure-Response Analysis to Inform QT Prolongation Potential for Cedirogant
Favorite
5:00 PM – 7:00 PM
ET
047: How Much PK Data Do We Really Need in Phase 3? A Milvexian Case Study
Favorite
5:00 PM – 7:00 PM
ET
048: Population Pharmacokinetic and Exposure-response Analyses of anti-BDCA2 Antibody Litifilimab Support Its Clinical Benefit for Cutaneous Lupus Erythematosus
Favorite
5:00 PM – 7:00 PM
ET
049: Assessment of the Effect of HBV Viral Genotype on Bepirovirsen Efficacy Using a Population Pharmacokinetic/Pharmacodynamic Modeling Approach
Favorite
5:00 PM – 7:00 PM
ET
050: Modeling Effects of Lymphodepletion Therapy on CAR T-cell & Cytokine Dynamics
Favorite
5:00 PM – 7:00 PM
ET
051: Pharmacokinetically-Guided Dosing of Fludarabine for Lymphodepletion in CAR T-cell Therapy: A Clinical Trial Simulation Study
Favorite
5:00 PM – 7:00 PM
ET
052: Nipocalimab Pharmacokinetic/Pharmacodynamic & Exposure-Response Modeling in Pregnancies at Risk for Early-onset Severe (EOS) HDFN
Favorite
5:00 PM – 7:00 PM
ET
053: Concentration-QTc Analysis of Quemliclustat in Combination With/Without Zimberelimab & nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Cancer
Favorite
5:00 PM – 7:00 PM
ET
054: The Effect of Moderate Hepatic Impairment on ONC201 (Dordaviprone) Pharmacokinetics
Favorite
5:00 PM – 7:00 PM
ET
055: First-in-Human Population PKPD Modelling & Simulation of CUE-101: Preliminary Results
Favorite
5:00 PM – 7:00 PM
ET
056: Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-targeted Loncastuximab Tesirine With Epcoritamab in B-cell Lymphoma
Favorite
5:00 PM – 7:00 PM
ET
057: Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab & Glofitamab Guides Dosing in B-cell Lymphoma
Favorite
5:00 PM – 7:00 PM
ET
059: Perioperative Antibiotic Prophylaxis in Paediatric Cardiac Surgery – is One Day Sufficient to Prevent Surgical Site Infections?
Favorite
5:00 PM – 7:00 PM
ET
060: Pharmacokinetic Modeling of the IRF5 Antisense Oligonucleotide JNJ-66525433 & IRF5 mRNA Expression in Healthy Individuals
Favorite
5:00 PM – 7:00 PM
ET
061: First-in-Human Evaluation of Pharmacokinetics & Safety of Tilpisertib Fosmecarbil, an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor, in Healthy Volunteers
Favorite
5:00 PM – 7:00 PM
ET
062: Absolute Oral Bioavailability of Nerandomilast in Healthy Male Study Participants
Favorite
5:00 PM – 7:00 PM
ET
063: Preclinical & Clinical Pharmacokinetics of JNJ-75220795, A siRNA Therapeutic Targeting
PNPLA3
, for Metabolic-associated Steatohepatitis
Favorite
5:00 PM – 7:00 PM
ET
064: Pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian Healthy Adults & Adults With Uncomplicated Malaria
Favorite
5:00 PM – 7:00 PM
ET
065: Clinical Pharmacological Characterization of Cilta-cel, a CAR-T Therapy Directed Against BCMA in Adult Patients With Multiple Myeloma in a Multicohort CARTITUDE-2 Study
Favorite
5:00 PM – 7:00 PM
ET
066: Population Pharmacokinetic Analysis of Cenobamate
Favorite
5:00 PM – 7:00 PM
ET
067: The Impact of Late-Runner Participants on PK Variability in Healthy Volunteer, Single-Ascending Dose Trials
Favorite
5:00 PM – 7:00 PM
ET
068: Pharmacokinetic Analyses & Population Pharmacokinetic Modeling of Maplirpacept in Patients With Newly Diagnosed Acute Myeloid Leukemia
Favorite
5:00 PM – 7:00 PM
ET
069: Population Pharmacokinetics of Bictegravir in Pregnant & Postpartum Persons Living With HIV
Favorite
5:00 PM – 7:00 PM
ET
070: Population Pharmacokinetic & Exposure-Response Analyses for the Phase 3 PhALLCON Study of Ponatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Favorite
5:00 PM – 7:00 PM
ET
071: Evaluation of Palbociclib & Combinatorial Chemotherapy Pharmacokinetics in Pediatric Patients With Recurrent or Refractory Solid Tumors
Favorite
5:00 PM – 7:00 PM
ET
072: Pharmacokinetics & Pharmacodynamics of Milvexian After Administration Every 12 Hours in Healthy Subjects
Favorite
5:00 PM – 7:00 PM
ET
073: Clinical Pharmacology of Bemarituzumab in Gastric & Gastroesophageal Junction Cancer Patients Supports the Interchangeability of Q2W & Q3W Dosing Regimens
Favorite
5:00 PM – 7:00 PM
ET
074: A First-in-Human, Single & Multiple Ascending Dose Study of CK-4021586, A Novel Cardiac Myosin Inhibitor
Favorite
5:00 PM – 7:00 PM
ET
075: Population Pharmacokinetics of Trastuzumab Deruxtecan (T-DXd) in Subjects With HER2-mutant & HER2-overexpressing Non-Small Cell Lung Cancer (NSCLC)
Favorite
5:00 PM – 7:00 PM
ET
076: First-in-Human Phase 1 SAD, MAD, Food Effect & DDI Study of SGR-1505, a Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor, in Healthy Volunteers
Favorite
5:00 PM – 7:00 PM
ET
077: Advanced Waveform Analysis of ECG Signals to Characterise Cardiac Drug Safety Between Caucasian & Japanese Volunteers
Favorite
5:00 PM – 7:00 PM
ET
078: Pharmacokinetics, Pharmacodynamics & Safety of Rusfertide, A Hepcidin Mimetic, in Subjects With Hepatic Impairment & in Subjects With Renal Impairment
Favorite
5:00 PM – 7:00 PM
ET
079: Exploring the Impact of Hepatic Impairment on the Pharmacokinetics of New Molecular Entities: A Comprehensive Analysis of Labeling Information
Favorite
5:00 PM – 7:00 PM
ET
080: Is it Time to Retire Cockcroft-Gault & “Original” Schwarz Formulas in Drug Development?
Favorite
5:00 PM – 7:00 PM
ET
081: Exclusion of Pediatric Patients With Renal Impairment in Clinical Trials for Antiviral Products
Favorite
5:00 PM – 7:00 PM
ET
082: Mechanistic Physiologically-based Pharmacokinetic Modeling to Predict Bictegravir Drug Disposition in Pregnancy
Favorite
5:00 PM – 7:00 PM
ET
083: Pharmacokinetics of Tenofovir Alafenamide, Emtricitabine & Dolutegravir in a Patient on Peritoneal Dialysis
Favorite
5:00 PM – 7:00 PM
ET
084: Exploration of Estimated Renal Function & Gabapentin Clearance in Older Adults
Favorite
5:00 PM – 7:00 PM
ET
085: Predicting Metoprolol Exposure-Response in Pregnant Population Using Physiologically-based Pharmacokinetic Modeling
Favorite
5:00 PM – 7:00 PM
ET
087: Development of a Pharmacokinetic-Tumor Target Engagement Model Using Nonclinical Data to Inform Phase 1 Dosing Scheme for a Novel Bispecific CD40-EpCAM Antibody, KK2269
Favorite
5:00 PM – 7:00 PM
ET
088: Developing a Physiologically-based Pharmacokinetic Model Across Various Species Exploring Drug Interaction Potential of Mitragynine
Favorite
5:00 PM – 7:00 PM
ET
089: The Impact of COVID-19 Mediated Bidirectional Dysregulation of CYP3A4 on Systemic & Pulmonary Candidate Drug Concentrations
Favorite
5:00 PM – 7:00 PM
ET
090: Pharmacokinetics of Tetrahydrocannabinol in Infants Exposed to Breastmilk from Recreational Cannabis Users
Favorite
5:00 PM – 7:00 PM
ET
150: The Gut-immune-liver Axis in Patients With Alcohol Use Disorder & Clinically Low Serum Zinc Levels
Favorite
